ABVC Stock — ABVC Biopharma Inc

ABVC Biopharma Inc (ABVC)

Updated October 2, 2026.

ABVC is a Stock. Its deepest 1-year drawdown was 78.4%.

ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs and medical devices for unmet medical needs, including treatments for triple negative breast cancer, depression, ADHD, myelodysplastic syndromes, retinal conditions, lung cancer, and pancreatic cancer, with multiple programs in Phase I and Phase II clinical trials. The company does not currently distribute to shareholders. ABVC BioPharma appeals to investors seeking exposure to early-stage biotech development, though clinical-stage companies carry substantial risk of development failure.

ABVC performance

Its deepest 1-year drawdown was 78.4%.

ABVC key facts

Asset type

Stock

Asset class

Equity

Inception date

11/10/2004

Distribution frequency

None

Last close

$1.01 (as of 2026-10-02)

Market cap

$26,920,909

Average volume

98100.0

Last payment date

05/08/2019

Beta

0.612

Payout ratio

0.0%

Forward P/E

0.0

EPS

$-0.29

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ABVC risks and drawbacks

The deepest 1-year drawdown on record here is 78.4%.

Who may consider ABVC — and who may not

It is a weaker fit for investors who need monthly cash flow (ABVC does not currently distribute); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Frequently asked questions